{
    "2021-09-09": [
        [
            {
                "time": "",
                "original_text": "疫苗板块2021H1总结：新冠疫苗商业化价值初现 在研管线亮点颇多",
                "features": {
                    "keywords": [
                        "疫苗",
                        "新冠疫苗",
                        "商业化",
                        "在研管线"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "西南证券：维持华兰生物(002007.SZ)“持有”评级 血制品收入短期下降 盈利能力下降",
                "features": {
                    "keywords": [
                        "西南证券",
                        "华兰生物",
                        "血制品",
                        "收入下降",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}